rAAV2-shmTOR-GFP (CuroGene Life Sciences/University of Ulsan)

N/A

Report date: 2025/01/26 16:57:06
NME

Base Information

Drug NamerAAV2-shmTOR-GFP (CuroGene Life Sciences/University of Ulsan)
Drug Alias Namerecombinant adeno-associated virus based gene therapy (CuroGene Life Sciences/University of Ulsan)shRNA targeting mTOR (CuroGene Life Sciences/University of Ulsan)mTOR-inhibiting shRNA (CuroGene Life Sciences/University of Ulsan)rAAV2-shmTOR-SD (CuroGene Lifesciences)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitors
TargetsSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsDiabetic RetinopathyRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCurogene Life Sciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCurogene Life Sciences Co LtdUniversity Of Ulsan
Inactive CompaniesN/A
Active IndicationsDiabetic RetinopathyRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A